Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01838876 · ClinicalTrials.gov registry record · Phase 3
Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder
A Phase 3 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 442
- Enrollment target
NCT01838876 is a Phase 3 study that has completed, run by Forest Laboratories. The registered enrollment target is 442 participants.
The verdict
NCT01838876, a Phase 3 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 442 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the long-term safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with Major Depressive Disorder (MDD).
Interventions
- DRUG Cariprazine
- DRUG Antidepressant Therapy (ADT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 442 participants |
| Start Date | 2013-04-29 |
| Est. Completion | 2015-07-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01838876
The ClinicalTrials.gov registry entry for NCT01838876 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 442 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cariprazine is the first listed.
NCT01838876 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01838876 about?
NCT01838876 is a clinical study titled "Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder". The objective of this study is to evaluate the long-term safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with Major Depressive Disorder (MDD).
What is the current status of trial NCT01838876?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 442 participants. The study started on 2013-04-29. Estimated completion is 2015-07-27.
What interventions are being tested in trial NCT01838876?
The interventions under investigation include: Cariprazine (DRUG), Antidepressant Therapy (ADT) (DRUG).
Who is sponsoring clinical trial NCT01838876?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.